Pharmaceutical Industry Executive Dr. Sidney Mazel Joins PRTM as Executive Vice President

Dr. Sidney Mazel joins global management consulting firm PRTM as executive vice president of transaction services for the health care business group. In this role, he will manage PRTM's acquisition, divestiture and integration services for the firm's biopharmaceutical, medical device, health care service and private equity clients.

Dr. Mazel has nearly 20 years of experience within the biopharmaceutical industry. He has held clinical, consulting and senior commercial positions at MedImmune, Merck, Wyeth (now part of Pfizer) and a previous role with PRTM. Most recently, Dr. Mazel served as an executive officer and senior vice president of product planning and portfolio management at MedImmune, with joint oversight for all product development programs, alliances and new product planning. He also served as a member of MedImmune's executive committee and co-chaired the product development committee before the company was acquired by AstraZeneca.

Prior to MedImmune, Dr. Mazel served as vice president of Global Marketing Planning at Merck, where he oversaw the strategic planning and growth of FOSAMAX from $700 million to more than $3 billion in sales. He also helped build the strategy and commercialization planning for the $2.8 billion global Arthritis & Analgesia Business, resulting in commercial leadership in seven of 10 global markets. Dr. Mazel received several patents that were licensed back to Merck and successfully commercialized, including FOSAVANCE, a combination product for osteoporosis still on the market today.

Dr. Mazel returns to PRTM, where, in the late 1990s he served as a principal in the life sciences business group and co-founded the firm's Washington, DC office. He says, of his return to PRTM, "There's a strong collegial spirit here, with bright and interesting people who are passionate about what they do. It's a stimulating environment, where you can collaborate with your colleagues to look at a business problem in a creative but pragmatic way. The clients ultimately benefit as they get an experienced team that brings a unique understanding of their organizational issues."